Hortoni General Hospital, Banbury (RECEIVED FOR PUBLICATION MARCH 26, 1953) Toxic purpura occurring in persons who have previously been sensitized by drug-taking often manifests itself with great rapidity in a matter of a few hours. Thrombocytopenia which may accompany this type of purpura can also occur in a very short time. If the natural life-span of platelets is about five days (Lawrence and Valentine, 1947; Hirsch and Gardner, 1952 ) then this rapid onset of thrombocytopenia seems to indicate a peripheral destruction of platelets rather than a central failure of production. Experiments by Ackroyd (Ackroyd, 1949a, b, and c, 1951) on the blood of patients recovering from " sedormid " purpura demonstrated it vitro the probable mechanism of platelet destruction in this condition. He has shown that " sedormid " added to blood from his patients in concentrations such as might be attained in vivo caused agglutination, and, in the presence of complement, lysis of the platelets. He found that a plasma factor was necessary for this action, and that in the presence of complement and " sedormid " plasma from his patient would cause agglutination and lysis of normal platelets.
We have carried out similar investigations on three cases of thrombocytopenic purpura which appeared to be related aetiologically to sensitization by quinine, sulphamezathine, and quinidine. For Case 3 0.05 ml. of a saturated solution of quinidine sulphate in saline was mixed in a siliconecoated tube at room temperature with 5.05 ml. of heparinized blood from the patient when in remission. Well-marked platelet agglutination occurred within one hour, but in this case no platelet lysis was observed. The platelet count on the supernatant plasma revealed a slow progressive fall in platelet concentration over several hours (Table III) . This was not the result of platelet lysis as far as could be determined by the stained film, but was probably due to sedimentation of the platelet masses. Simultaneous experiments with phenobarbitone and quinine failed to demonstrate platelet agglutination, suggesting that the patient had not acquired sensitivity to phenobarbitone, and that there was no cross-sensitivity to quinine, the stereoisomer of quinidine.
Control experiments using normal blood samples and the same solutions of quinine, quinidine, sulphamezathine, and phenobarbitone failed to cause platelet loss, agglutination, or lysis in the supernatant plasma (Tables IVa and IVb Platelet-free plasma, obtained from the heparinized blood of this patient by centrifuging at high speed, was able to cause agglutination of platelets in normal platelet-rich plasma in the presence of quinidine sulphate (Table V) . No platelet lysis was detected in this experiment. It was observed that, when the patient's plasma was stored frozen solid for more than two days,* the ability to agglutinate platelets in the presence of quinidine sulphate was lost. The addition of normal fresh human serum restored this power without affecting the control tube. The nature of the serum factor was not investigated. As quinidine sulphate is only sparingly soluble in saline it was thought that the absence of lysis in these experiments might be due to an insufficiency of quinidine in the test blood. Accordingly 0.05 ml. of 0.14% quinidine lactate in saline was used; this, however, did not materially alter the experimental results.
* "Complement" d-teriorates only slowly in frozen serum.
In Cases 1 and 3 saline suspensions of washed platelets were made, and anti-human globulin serum was added in an attempt to detect a possible coating antibody. There appeared to be no increase in the agglutination of these washed platelets, despite the natural tendency of these saline suspensions of platelets to agglutinate to some degree.
In none of these three patients were we able to cause local purpura, or increase in local capillary fragility by patch-testing with watery suspensions of the appropriate drug.
Discussion
It has been shown in Cases 1 and 2 that rapid in vitro agglutination and lysis of platelets followed the addition of quinine and of sulphamezathine to the blood of these patients. Case 3 was shown to possess a plasma factor which, in the presence of normal platelets, quinidine, and a serum factor, was able to cause platelet agglutination. The disease process in this patient was mild compared with Cases 1 and 2, and corresponded roughly with Ackroyd's third case in severity.
Further examples of what might well be called the " Ackroyd phenomenon " have been described in two cases of quinidine purpura (Bigelow and Desforges, 1952) , in one of which the plasma rather than the platelets was at fault. A case of quinine purpura (Grandjean, 1948) has been described, when it was noted that the addition of quinine to platelet-rich plasma from the patient resulted in a significant fall in the platelet count. None of the nine patients in whom this phenomenon has been demonstrated had developed purpura on first taking the offending drugs; presumably an acquired sensitivity to the drug had developed. It was not clear from the history of our third case whether phenobarbitone or quinidine was likely to be responsible for the purpura ; however, the investigations seemed to point to quinidine as the cause of the disease.
It is possible that thrombocytopenic purpura occurring as an acquired sensitivity to drugs other than " sedormid," sulphamezathine, quinine, and quinidine may be associated also with this type of platelet agglutination, and it would probably be of value in diagnosis to determine the in vitro platelet agglutinating potentialities of the drug in question. It is recommended that glassware be rendered water-repellent before embarking on such an investigation. Conclusions Three cases of toxic thrombocytopenic purpura are described due to acquired sensitivity to quinine, sulphamezathine, and quinidine.
The addition of the offending drug to plateletrich plasma from each of these three patients readily caused platelet agglutination and lysis in two, and platelet agglutination only in the third. 
